Trials / NCT03490019
Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement
Withdrawn Phase 2 Drug / neuroprotection
Why it stopped: unrealizable wishes of national authorities
- Sponsor
- University Hospital Tuebingen
- Treatment
- Metformin
- Gene
- Not stated
- Conditions
- Bardet-Biedl Syndrome, Visual Impairment
- Ages
- 10 Years to 25 Years
- Enrollment
- Not stated participants
- Started
- 2018-04-01
- Main results expected
- 2019-10
- Results posted
- Not yet
- Record last updated
- 2019-04-18
What the study is testing
In this prospective pilot study without control group children and young adults (10-25 years old) diagnosed with Bardet-Biedl syndrome and treated with Metformin for their adipositas will be evaluated for a possible additional effect of Metformin on visual acuity.
Where it runs
No sites listed yet.